Fig. 8.

SLC-0111 increases the effect of Cis-Pt on metastatic spread in vivo. A Nude mice bearing orthotopic FaDu xenografts were treated with vehicle, SLC-0111 (100 mg/kg per os administration, via oral gavage) or Cis-Pt alone (3 mg/kg per i.p. injection), or the two drugs in combination, as reported in treatment schedule shown in Fig. 7A. At end of treatments FaDu xenografts were injected with 2 nmol of ProSense 750 and subjected to imaging studies using FRI at 2 h. B At end of imaging study, tumors, head-neck lymph nodes and lungs were harvested for ex vivo FRI analysis. Representative images as shown